Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, finasteride dose-dependently inhibited stress-induced increases in allopregnanolone in rats, while enhancing 20alpha-reduction of progesterone without affecting 3alpha-dihydroprogesterone or 11-deoxycorticosterone levels.

The researchers reported that during early embryogenesis and larval development in Silurana tropicalis, inhibiting steroidogenic enzymes cyp19 and srd5beta affects genes related to thyroid and reproductive systems.

Both drugs lower DHT levels, with GI198745 being more effective.

This study suggests that finasteride-loaded liquid crystalline nanoparticles could be a viable alternative to oral administration for treating androgenetic alopecia due to their controlled release and skin permeation properties.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

Higher IGF-1 levels in hair follicles link to better finasteride results for hair loss.

This study found that liquid crystalline nanoparticles formulated with Cremophor surfactants significantly enhanced skin permeation of finasteride compared to lower surfactant concentrations.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This study found that progesterone pretreatment in rats potentiated the effect of ethanol on mesocortical dopamine levels, suggesting an influence of neuroactive steroids on ethanol's action.

This article contains additional supporting information available online but presents no new research findings.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

Method detects finasteride in plasma and semen with high sensitivity and accuracy.

This pharmacovigilance study found an increased association of suicidality and psychological adverse events with finasteride use, especially among younger patients using it for alopecia.

This study found that the developed Finasteride-loaded SMEDDS improved the relative bioavailability of the drug compared to a commercial tablet, offering a promising oral delivery system for glucosteroid analogs.

This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

The study observed that finasteride reduced fertility in male Sprague-Dawley rats by impairing the formation of copulatory plugs, an effect considered specific to rats and not applicable to species without this reproductive feature.

This study found that finasteride increased fetal arousal activity in late gestation sheep by suppressing pregnane steroid synthesis, suggesting reduced GABAA receptor-mediated inhibition.

This study found that finasteride treatment decreased VEGF expression in the prostate tissue of patients with benign prostatic hyperplasia, although it did not affect vascular density or serum VEGF levels.

In this study, finasteride altered acute ethanol withdrawal severity differently in male and female mice, highlighting sex differences in sensitivity to changes in neurosteroid levels.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This study found that subchronic finasteride treatment in male rats altered neuroactive steroid levels and steroid receptor expression in the brain, with some changes persisting after drug withdrawal.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

This study found that using drug microplates in transdermal finasteride films enhances aqueous solubility and skin permeation compared to films with pure finasteride.

In this study of men with androgenetic alopecia, daily finasteride 1 mg alongside hair transplant improved scalp hair density and growth of nontransplanted hair compared to placebo over 48 weeks.

This study developed a fully automated HPLC method for accurately quantifying finasteride in human plasma, achieving a detection limit of 1 ng/ml with validated application in pharmacokinetic studies.

In this study, finasteride treatment did not negatively impact bone development or density in male rats, suggesting that DHT deficiency is not harmful to the male rat skeleton.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.